Last reviewed · How we verify
NCT06751134
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Phase 1 trial testing Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) in Neuroblastoma, Recurrent, Refractory in 12 participants. Currently enrolling.
1 July 2026
Quick facts
| Lead sponsor | Nanjing Children's Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 28 December 2024 |
| Primary completion | 1 July 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) — full drug profile →
Conditions studied
- Neuroblastoma, Recurrent, Refractory — all drugs for Neuroblastoma, Recurrent, Refractory →
Sponsor
Nanjing Children's Hospital
Who can join
Adults 1 to 12, any sex, with Neuroblastoma, Recurrent, Refractory. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, preliminary efficacy, pharmacokinetics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with relapsed/refractory Neuroblastoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06751134
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
Trials testing the same drug.
- NCT06750133 — Universal CNK-UT Therapy for Refractory aGVHD · Phase 1 · recruiting
- NCT06568328 — Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD · Phase 1 · recruiting
Other Nanjing Children's Hospital trials
Trials by the same sponsor.
- NCT07095816 — Acetaminophen Before Surgery Lowers Postop Pain in Pediatric Solid Tumor Patients (ERAS) · Phase 1 · completed
- NCT06275022 — A Prospective Study on the Treatment of cLM Based on ICG Imaging · NA · recruiting
- NCT07257276 — 3D-CT-Based Prediction of Difficult Laryngoscopy in Infants With Pierre Robin Sequence · active not recruiting
- NCT05716230 — Bowel Function and Associated Risk Factors for Bowel Dysfunciton in Patients With Anorectal Malformation · unknown
- NCT05564819 — Efficacy and Safety of Acetaminophen in Postoperative Pain Management of Infants · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06751134 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing Children's Hospital
- Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06751134.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing